Anesthesia, General Clinical Trial
Official title:
Influence of the MTHFR 677C>T Mutation on Homocysteine Levels After Nitrous Oxide Anesthesia.
Our study looks at the interaction of a common mutation in the MTHFR gene and the risk of
developing higher homocysteine levels after nitrous oxide (N2O) anesthesia.
Specifically, we want to test the hypothesis that healthy patients carrying the MTHFR 677C>T
haplotype develop abnormal homocysteine levels after nitrous oxide anesthesia.
Nitrous oxide – laughing gas – is a widely used anaesthetic gas with many favourable but
also some dangerous properties. Among the latter is the increase in homocysteine levels
after nitrous oxide (N2O) exposure by inhibition of enzymes in the vitamin B12 pathway.
Elevated homocysteine levels have been found to be an independent risk factor for ischemic
events and are associated with an increased risk for perioperative myocardial ischemia. If a
patient carries one or more loss-of-function mutations in enzymes of the
methionine/homocysteine/folate pathway he is at an increased risk for hyperhomocysteinemia
and if exposed to N2O might suffer severe, sometimes disastrous neurological damage.
Recently, a case report in the New England Journal of Medicine reported the death of a child
with an enzyme defect in the MTHFR gene after anaesthesia with nitrous oxide (NEJM
2003;349:45-50).
Thus, we are convinced that if we can determine the risk of patients who carry mutations in
the MTHFR gene and undergo anaesthesia with N2O for developing pathological levels of
homocysteine, we can add an important piece of information to the safety profile of N2O.
Our study tests the hypothesis that patients who carry the 677C<T mutation in the MTHFR gene
(the most common mutation) have a higher risk of developing hyperhomocysteinemia after N2O
anaesthesia.
;
Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06063798 -
Respiratory Effects of Flow-Controlled Ventilation and Jet Ventilation in Patients Undergoing Laryngotracheal Surgery
|
N/A | |
Not yet recruiting |
NCT05035069 -
Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR
|
Phase 4 | |
Completed |
NCT03861364 -
Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose.
|
Phase 4 | |
Completed |
NCT02711280 -
The Effect of Anesthetics on Oxidative Stress and Apoptosis Status in Children
|
N/A | |
Completed |
NCT01199471 -
Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane
|
N/A | |
Completed |
NCT00917033 -
Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy
|
Phase 4 | |
Completed |
NCT00391885 -
Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy
|
Phase 4 | |
Completed |
NCT00552617 -
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
|
Phase 2 | |
Completed |
NCT03705026 -
Relationship Between Genetic Polymorphism and Postoperative Nausea and Vomiting in Chinese Han Population
|
||
Completed |
NCT00552929 -
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
|
Phase 2 | |
Completed |
NCT00475215 -
Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)
|
Phase 3 | |
Completed |
NCT00298831 -
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
|
Phase 3 | |
Recruiting |
NCT03943745 -
EEG Changes During Induction of Propofol Anesthesia
|
||
Completed |
NCT03697642 -
Nasopharyngeal Airway Guide Nasogastric Tube Placement
|
N/A | |
Completed |
NCT04595591 -
Observation of Propofol Titration at Different Speeds
|
N/A | |
Not yet recruiting |
NCT05841316 -
The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block
|
||
Completed |
NCT04532502 -
Impact of Anesthetic Environment the Sex Ratio of the Children of Female Assistants
|
||
Completed |
NCT03330236 -
EEG - Guided Anesthetic Care and Postoperative Delirium
|
N/A | |
Recruiting |
NCT06205212 -
High-flow Nasal Oxygenation During Preoxygenation and Atelectasis
|
N/A | |
Completed |
NCT00379613 -
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
|
Phase 2 |